These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 11408781)

  • 21. Effects of estradiol with micronized progesterone or medroxyprogesterone acetate on risk markers for breast cancer in postmenopausal monkeys.
    Wood CE; Register TC; Lees CJ; Chen H; Kimrey S; Cline JM
    Breast Cancer Res Treat; 2007 Jan; 101(2):125-34. PubMed ID: 16841178
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effective bleeding control and symptom relief by lower dose regimens of continuous combined hormone replacement therapy: a randomized comparative dose-ranging study.
    Bruhat M; Rudolf K; Vaheri R; Kainulainen P; Timonen U; Viitanen A
    Maturitas; 2001 Dec; 40(3):259-71. PubMed ID: 11731187
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of continuous combined conjugated estrogen/medroxyprogesterone acetate and 17beta-estadiol/norethisterone acetate on lipids and lipoproteins.
    Odmark IS; Bäckström T; Haeger M; Jonsson B; Bixo M
    Maturitas; 2004 Jun; 48(2):137-46. PubMed ID: 15172088
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A two-year double-blind controlled study of the clinical effect of combined and sequential postmenopausal replacement therapy and steroid metabolism during treatment.
    Obel EB; Munk-Jensen N; Svenstrup B; Bennett P; Micic S; Henrik-Nielsen R; Nielsen SP; Gydesen H; Jensen BM
    Maturitas; 1993 Jan; 16(1):13-21. PubMed ID: 8429800
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transdermal sequential and continuous hormone replacement regimens with estradiol and norethisterone acetate in postmenopausal women: effects on the endometrium.
    Johannisson E; Holinka CF; Arrenbrecht S
    Int J Fertil Womens Med; 1997; 42 Suppl 2():388-98. PubMed ID: 9397386
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The differential effect of estrogen, estrogen-progestin and tibolone on coagulation inhibitors in postmenopausal women.
    Keramaris NC; Christodoulakos GE; Lambrinoudaki IV; Dalamanga A; Alexandrou AP; Bramis J; Bastounis E; Creatsas GC
    Climacteric; 2007 Oct; 10(5):400-7. PubMed ID: 17852143
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term effects of two different continuous combined regimens of hormone replacement therapy on well-being.
    Odmark IS; Bäckström T; Jonsson B; Bixo M
    Gynecol Endocrinol; 2004 Jun; 18(6):305-17. PubMed ID: 15497493
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of two different regimens of continuous hormone replacement therapy on endometrial histopathology and postmenopausal uterine bleeding.
    Yildirim G; Tugrul S; Uslu H; Pekin O; Eren S
    Arch Gynecol Obstet; 2006 Feb; 273(5):268-73. PubMed ID: 16315025
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Economic impact of tibolone compared with continuous-combined hormone replacement therapy. In the management of postmenopausal women with climacteric symptoms in the UK.
    Plumb JM; Guest JF
    Pharmacoeconomics; 2000 Nov; 18(5):477-86. PubMed ID: 11151401
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects on serum lipid profiles of continuous 17beta-estradiol, intermittent norgestimate regimens versus continuous combined 17beta-estradiol/norethisterone acetate hormone replacement therapy.
    Ylikorkala O; Lim P; Caubel P
    Clin Ther; 2000 May; 22(5):622-36. PubMed ID: 10868559
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of postmenopausal hormone replacement therapy on body fat composition.
    Yüksel H; Odabasi AR; Demircan S; Köseoğlu K; Kizilkaya K; Onur E
    Gynecol Endocrinol; 2007 Feb; 23(2):99-104. PubMed ID: 17454160
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patients with premenstrual syndrome have a different sensitivity to a neuroactive steroid during the menstrual cycle compared to control subjects.
    Sundström I; Andersson A; Nyberg S; Ashbrook D; Purdy RH; Bäckström T
    Neuroendocrinology; 1998 Feb; 67(2):126-38. PubMed ID: 9508043
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Monofluorophosphate combined with hormone replacement therapy induces a synergistic effect on bone mass by dissociating bone formation and resorption in postmenopausal women: a randomized study.
    Alexandersen P; Riis BJ; Christiansen C
    J Clin Endocrinol Metab; 1999 Sep; 84(9):3013-20. PubMed ID: 10487657
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimal tolerability of ultra-low-dose continuous combined 17beta-estradiol and norethisterone acetate: laboratory and safety results.
    Samsioe G; Hruska J;
    Climacteric; 2010 Feb; 13(1):34-44. PubMed ID: 20001563
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of oral continuous 17beta-estradiol plus norethisterone acetate replacement therapy on abdominal subcutaneous fat, serum leptin levels and body composition.
    Yüksel H; Odabaşi AR; Demircan S; Karul A; Kozaci LD; Köseoğlu K; Kizilkaya K; Başak O
    Gynecol Endocrinol; 2006 Jul; 22(7):381-7. PubMed ID: 16864148
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevention of postmenopausal bone loss with long-cycle hormone replacement therapy.
    Popp AW; Bodmer C; Senn C; Fuchs G; Kraenzlin ME; Wyss H; Birkhaeuser MH; Lippuner K
    Maturitas; 2006 Jan; 53(2):191-200. PubMed ID: 16368472
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Progestins used in hormonal replacement therapy display different effects in coronary arteries from New Zealand white rabbits.
    Pedersen NG; Pedersen SH; Dalsgaard T; Lund CO; Nilas L; Ottesen B
    Maturitas; 2004 Dec; 49(4):304-14. PubMed ID: 15531126
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of a continuous-combined regimen of low-dose hormone therapy (oestradiol and norethindrone acetate) and tibolone on the quality of life in symptomatic postmenopausal women: a double-blind, randomised study.
    Polisseni AF; Andrade AT; Ribeiro LC; Castro IQ; Brandão M; Polisseni F; Guerra Mde O
    Maturitas; 2013 Feb; 74(2):172-8. PubMed ID: 23201326
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of various menopausal hormone therapies on markers of inflammation, coagulation, fibrinolysis, lipids, and lipoproteins in healthy postmenopausal women.
    Zegura B; Guzic-Salobir B; Sebestjen M; Keber I
    Menopause; 2006; 13(4):643-50. PubMed ID: 16837886
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relationship between menopausal hormone therapy and breast cancer: A nationwide population-based cohort study.
    Yuk JS
    Int J Gynaecol Obstet; 2024 Aug; 166(2):735-744. PubMed ID: 38469634
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.